Floatz logo

rc48

Disitamab Vedotin

Sun Yat-sen Universityantibody_drug_conjugatePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Disitamab Vedotin cohort.

Asset / SponsorPhaseRating
Osimertinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Carboplatin
Sun Yat-sen University
Phase 2CCC
Pyrotinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Tislelizumab
Sun Yat-sen University
Phase 2CCC
rc48-adc
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC
Famitinib
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2CCC

Same molecule, other indications

rc48 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
RC48Dormant
CCC
Indicative ·
53 / 100
View asset →
ERBB2 Mutation-Related TumorsDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →